I think he was referring only yo the GBM indication where they will not need much of a sales force as they are already at over 90 of the main locations that treat GBM. He did indicate they are open to partnership for the other solid tumors where they do need to build up a significant sales force. They just need to pay up!
Agreed, but they seem to indicate they don’t have a big pharma lined up for GBM commercialization yet. Bigger seems to think we may be in for another disappointment post MAA submission/acceptance so he wants to take up an activist role, if needed. If a big pharma involvement was around the corner post UK approval, there is no need for him to be involved.
For GBM they wouldn’t need much of a sales team as the world will beat a path to the treatment given its breakthrough only game in town (the world actually) status offering the best chance to extend survival.
Les mentioned there’s a backlog and waiting list for the UK specials program access to treatment already pre approval.
Hiring and scaling to handle the increasing volume of production will likely be the limiting factor if any.
Check out the Sawston hiring efforts!
Dealing with regulatory compliance is always a challenge as well but limiting production facilities should help keep things under control.